NCT05293028

Study of F527 in Patients With Relapsed or Refractory Lymphoma

Phase I Clinical Study of Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of F527 in the Treatment of Patients With Relapsed or Refractory Lymphoma

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 82 (estimated)
• Sponsor: Shandong New Time Pharmaceutical Co., LTD · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is a non-randomized, open-label, phase I dose-finding and dose-expansion study to evaluate the safety, tolerability, antitumor efficacy, PK and immunogen of F527 in patients with relapsed or refractory lymphoma sexual characteristics.

Conditions

• Relapsed/Refractory Lymphoma

Interventions

Type	Name	Description
DRUG	F527	0.001、0.01、0.1、0.3、1、3 and10 mg/kg QW

Timeline

• Start date: 2022-05-20
• Primary completion: 2023-11-20
• Completion: 2024-05-20
• First posted: 2022-03-23
• Last updated: 2022-03-23

Locations

1 site across 1 country: China